SCHEMBL25317005

SCHEMBL25317005

CCc1cc2ccc(Br)cc2[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
KDM4E B2RXH2 6/20 0.49
HSD17B10 Q99714 6/20 0.49
DAO P14920 1/20 0.47
TSHR P16473 3/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
MAPT P10636 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8076756 0.80 DAO (0.56) ALDH1A1KDM4EHSD17B10DAOTSHR
SCHEMBL3715876 0.79 EGFR (0.53) ALDH1A1KDM4EHSD17B10TSHRCYP1A2
SCHEMBL29892803 0.79 BRD4 (0.59) ALDH1A1KDM4EHSD17B10DAOGRIN2D
SCHEMBL16627567 0.78 METAP2 (0.46) DAOTP53
SCHEMBL30493556 0.77 DAO (0.60) ALDH1A1KDM4EHSD17B10DAOTSHR
SCHEMBL30663247 0.77 DAO (0.56) ALDH1A1KDM4EHSD17B10DAOTSHR
SCHEMBL25912136 0.77 EIF4A3 (0.53) ALDH1A1KDM4EHSD17B10DAOTSHR
SCHEMBL25093890 0.77 DAO (0.60) ALDH1A1KDM4EHSD17B10DAOTSHR
SCHEMBL25093894 0.77 DAO (0.56) ALDH1A1KDM4EHSD17B10DAOTSHR
SCHEMBL26992268 0.77 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10DAOTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221987-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-07-10 US disclosed
WO-2025011494-A1 CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE 优领医药科技(香港)有限公司 2025-01-16 WO disclosed
EP-4464704-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Acerand Therapeutics (Hong Kong) Limited (HK) 2024-11-20 EP disclosed
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 WO disclosed
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 WO disclosed
CN-116425744-A Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof 优领医药科技(香港)有限公司 2023-07-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221987-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF PARP1, PARP11, PARP15 ALDH1A1 543/4885KDM4E 1630/4885HSD17B10 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.